Skip to main content
SBRASabra Health Care REIT, Inc.Hold6.1·$18.50-0.43%
Open full analysis

Sabra Health Care REIT, Inc. (SBRA) Stock Analysis

HoldModerate Confidence

Real Estate · REIT - Healthcare Facilities

Hold if already holding. Not a fresh buy at $18.50, but acceptable to hold if already in. Reasons: Thin upside margin: 6.7%; Negative momentum.

Sabra Health Care REIT owns and invests in 360 healthcare properties across the U.S. and Canada, primarily skilled nursing/transitional care facilities (58.3% of portfolio by count), senior housing communities, behavioral health facilities, and specialty hospitals leased to... Read more

$18.50+6.7% A.UpsideScore 6.1/10#2 of 13 REIT - Healthcare Facilities
QualityF-score8 / 9FCF yield4.22%
IncomeYield6.46%(5y avg 7.93%)Payout190.48%
Stop $17.32Target $19.81(analyst − 13%)A.R:R 1.0:1
Analyst target$22.77+23.1%13 analysts
$19.81our TP
$18.50price
$22.77mean
$25

Hold if already holding. Not a fresh buy at $18.50, but acceptable to hold if already in. Reasons: Thin upside margin: 6.7%; Negative momentum. Chart setup: No clear chart pattern; technical signals are mixed. Maintain position. Not compelling to add more. Score 6.1/10, moderate confidence.

Passes 6/8 gates (clean insider activity, no SEC red flags, news events none recent, earnings proximity 48d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and favorable risk/reward ratio. Suitability: aggressive.

10-K grounded · weekly refresh

About Sabra Health Care REIT, Inc.

About Sabra Health Care REIT, Inc.

Sabra Health Care REIT held 360 real estate properties at December 31, 2025, spanning skilled nursing/transitional care (210 facilities, 58.3% of portfolio), senior housing managed (87 communities, 24.2%), senior housing leased (32 facilities, 8.9%), behavioral health (16 facilities, 4.4%), and specialty hospitals (15 facilities, 4.2%), with total undepreciated book value of $5.909 billion. Texas represented the largest geographic concentration at 15.6% of total properties (56 facilities). The portfolio also included 13 loans receivable totaling $377 million in principal balance at a weighted-average contractual rate of 7.7% and four preferred equity investments of $65 million at 11.0%.

Sabra generates revenue primarily through triple-net leases on 273 facilities, under which tenants bear all property operating expenses, taxes, insurance, and maintenance. Leases run from less than one year to 18 years with a weighted-average remaining term of 7 years and generally include provisions to extend. The 87 Senior Housing - Managed communities operate under property management agreements where third-party managers receive a management fee while Sabra bears direct operational exposure to occupancy and rate fluctuations. The company's tenants depend heavily on Medicare, Medicaid, and private third-party payors for revenue, creating regulatory reimbursement risk. The filing notes CMS projects nursing home expenditures to grow from approximately $229 billion in 2024 to approximately $386 billion in 2033 at a 6.0% CAGR, providing a demand tailwind.

Show full overview

Sabra's single largest credit risk is tenant financial health rather than tenant concentration — the company explicitly states no tenant represented 10% or more of total revenues in 2025. However, its tenants face intensifying regulatory enforcement, potential Medicare/Medicaid reimbursement reductions (noted as a risk from President Trump and Congress), and labor cost inflation from minimum staffing requirements and wage pressures. The company's dependence on its President and CEO Mr. Matros is named explicitly as a key-person risk, and the 87 Senior Housing - Managed communities expose the balance sheet directly to occupancy and labor cost volatility rather than behind a NNN lease structure.

See also: Real Estate · REIT - Healthcare Facilities

From Sabra Health Care REIT, Inc.'s most recent 10-K filing, extracted June 11, 2026.

news + 30-day 8-K events · 5-min refresh

Recent developments

updated 2026-06-17
TrendMatrix Research · upcoming catalyst calendar

Upcoming dated catalysts

Mon, Aug 3, 202648d to earnings· next earnings call

Thesis

Rewards
High-quality business
Risks
Thin upside margin: 6.7%
Negative momentum

Key Metrics

P/E (TTM)29.5
P/E (Fwd)25.0
Mkt Cap$4.7B
EV/EBITDA15.8
Profit Mgn19.1%
ROE5.7%
Rev Growth21.7%
Beta0.63
Dividend6.46%
Rating analysts20

Quality Signals

Piotroski F8/9MoatNarrow

Options Flow

P/C0.16bullish
IV48%normal
Max Pain$23+21.6% vs spot

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.

Show full disclosure ▾

About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.

Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.

Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.

No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.

No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.

Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.

Methodology · Editorial policy & full disclaimer

Rating Breakdown

1 floor-breaker

Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static

Obv
1.0
Ma Position
2.2
Macd
3.2
Rsi
3.5
Volume
7.7
Volume distribution (falling OBV)Below 200-MA but MA still rising (+1.7%/30d) — pullback in uptrend, not confirmed weakness
GatesMomentum 3.5<4.5A.R:R 1.0 < 1.5@spotInsider activity: OKNo SEC red flagsNEWS EVENTS NONE RECENTEARNINGS PROXIMITY 48d clearSEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARSuitability: Aggressive
RSI
33 · Neutral
20D MA 50D MA 200D MAGOLDEN CROSSSupport $17.54Resistance $21.28

Price Targets

$17
$20
A.Upside+7.1%
A.R:R1.0:1

Position Sizing

ConvictionNone
Suggested %0.5%
Max %1%
RegimeSteady

Risk Alerts

! momentum at 3.5 (below the engine's 4.5 threshold)
! asymmetry at 1.0 (below the engine's 1.5 threshold)@spot

Earnings

B
M
M
M
1/4 beats
Next Earnings2026-08-03 (48d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is SBRA stock a buy right now?

Hold if already holding. Not a fresh buy at $18.50, but acceptable to hold if already in. Reasons: Thin upside margin: 6.7%; Negative momentum. Chart setup: No clear chart pattern; technical signals are mixed. Maintain position. Not compelling to add more. Target $19.81 (+7.1%), stop $17.32 (−6.8%), A.R:R 1.0:1. Score 6.1/10, moderate confidence.

What is the SBRA stock price target?

Take-profit target: $19.81 (+6.7% upside). Target $19.81 (+7.1%), stop $17.32 (−6.8%), A.R:R 1.0:1. Stop-loss: $17.32.

What are the risks of investing in SBRA?

Thin upside margin: 6.7%; Negative momentum.

Is SBRA overvalued or undervalued?

Sabra Health Care REIT, Inc. trades at a P/E of 29.5 (forward 25.0). TrendMatrix value score: 5.8/10. Verdict: Hold.

What do analysts say about SBRA?

20 analysts cover SBRA with a consensus score of 3.8/5. Average price target: $23.

What does Sabra Health Care REIT, Inc. do?Sabra Health Care REIT owns and invests in 360 healthcare properties across the U.S. and Canada, primarily skilled...

Sabra Health Care REIT owns and invests in 360 healthcare properties across the U.S. and Canada, primarily skilled nursing/transitional care facilities (58.3% of portfolio by count), senior housing communities, behavioral health facilities, and specialty hospitals leased to third-party operators. Revenue is generated through triple-net operating leases (273 facilities, weighted-average remaining term of 7 years) and management agreements for 87 Senior Housing - Managed communities, with no single tenant representing 10%+ of total revenues in 2025.

Related stocks: OHI (Omega Healthcare Investors, Inc) · MPT (Medical Properties Trust, Inc.) · SILA (Sila Realty Trust, Inc.) · AHR (American Healthcare REIT, Inc.) · CTRE (CareTrust REIT, Inc.)
Home Stocks SBRA

Latest news

Latest News

Investing.com UK21d ago
MarketBeat42d ago
Yahoo Finance14d ago
AD HOC NEWS36d ago
GuruFocus36d ago
Newsline.com8d ago
MarketBeat43d ago
TipRanks20d ago
Marketscreener.com20d ago
Marketscreener.com20d ago
TipRanks27d agoAnalyst
Newser.com41d ago
MarketBeat38d agoAnalyst
Investing.com UK37d agoAnalyst
MarketBeat37d ago
Yahoo Finance9d ago
MSN9d ago
GuruFocus16d agoAnalyst
MarketBeat16d ago
MarketBeat16d ago
Loading more...